DAPAVILD 50/5 Dapagliflozin (5mg), Vildagliptin SR (50mg) DAPAVILD 50/5 represents a progressive step in the management of type 2 diabetes, combining two potent active ingredients to optimize blood sugar control. This medication integrates the efficiency of Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with the consistent performance of Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. The formulation of DAPAVILD 50/5 offers a dual mechanism of action: Dapagliflozin works by preventing glucose reabsorption in the kidneys, leading to its excretion in urine, while Vildagliptin enhances insulin secretion and reduces the production of glucagon in the pancreas. This synergistic effect not only aids in lowering blood glucose levels but also assists in weight management and has potential cardiovascular benefits. Tailored for patients who require an intensified treatment approach, DAPAVILD 50/5 is a testament to innovation in diabetic care, providing a balanced and effective solution for managing type 2 diabetes.